Treating pain with novel non-opioid based drugs
Data-driven treatments for patients in need.
Data-driven treatments for patients in need.
A biotechnology company dedicated to developing non-opioid pain relief solutions, Alyea Therapeutics focuses on Complex Regional Pain Syndrome (CRPS) and other chronic pain conditions.
Spearheaded by Dr. Amol Soin, Alyea intends to transform pain management through innovation. Alyea’s proprietary lead product and key offering, Low Dose Naltrexone (LDN), will be entering late-stage clinical trials, significantly holding FDA orphan drug designation. Orphan status offers such benefits as market exclusivity, tax credits, and streamlined regulatory support. Alyea Therapeutics is a wholly owned subsidiary of ALT 5 Sigma Corporation (Nasdaq:ALTS) with plans to be spun out in the first half of 2025 as its own stand alone public company.
Nearly 20.9% of U.S. adults (51.6 million people) experience chronic pain, according to the U.S. Centers for Disease Control and Prevention (CDC).
The CDC estimates more than 108,000 drug overdose deaths occur each year.
Synthetic opioids were involved in an estimated 87% of opioid and 65% of all drug overdose deaths.
Alyea’s goal is revolutionizing pain management by advancing innovative solutions for the effective treatment of Complex Regional Pain Syndrome (CRPS). Our mission is improving the quality of life for patients globally and we are committed to innovative science.
Alyea’s leader, Amol Soin, MD, head of the Soin Medical Centre and Research Lab, has been recognized multiple times as one of America's top doctors. He received the Patient's Choice Award, an honor given only to the top 1% of the country’s physicians. Board certified in anesthesiology and pain medicine and a fellow of interventional pain management at the World Institute of Pain, he served as a pain management fellow at the Cleveland Clinic, the oldest and largest academic pain management department in the United States. He was instrumental in passing statewide rules and guidelines to combat the opioid crisis.
For more information about Alyea Therapeutics and its novel drug therapy, please click here.
Get in Touch